New England Journal of Medicine January 25, 2018

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma

Joseph M. Connors, Wojciech Jurczak, David J. Straus, Stephen M. Ansell, et al.

Bottom Line

The Phase 3 ECHELON-1 trial demonstrated that frontline treatment with brentuximab vedotin plus AVD improves modified progression-free survival and eliminates bleomycin-induced pulmonary toxicity compared to standard ABVD in advanced classical Hodgkin's lymphoma, though with increased risks of neuropathy and neutropenia.

Key Findings

1. At a median follow-up of 24.6 months, the 2-year modified progression-free survival (mPFS) was significantly higher in the A+AVD group compared to the ABVD group (82.1% vs. 77.2%; HR 0.77, 95% CI 0.60-0.98; P=0.04).

2. Interim overall survival did not significantly differ between the groups at the time of the primary analysis, with 28 deaths in the A+AVD arm and 39 in the ABVD arm (HR 0.73, 95% CI 0.45-1.18; P=0.20).

3. Grade 3 or higher pulmonary toxicity was significantly lower in the A+AVD arm (<1% vs. 3%). Among on-treatment deaths, 11 of 13 in the ABVD group were associated with pulmonary toxicity.

4. Peripheral neuropathy occurred more frequently in the A+AVD group (67% vs. 43%), though 67% of cases in the A+AVD arm resolved or improved by the last follow-up visit.

5. The incidence of febrile neutropenia was higher with A+AVD (19% vs. 8%). However, among A+AVD patients who received primary G-CSF prophylaxis, the rate dropped to 11% (compared to 21% without prophylaxis), and 7 of 9 on-treatment deaths in the A+AVD arm were associated with neutropenia.

Study Design

Design

Randomized Controlled Trial

Open-Label

Sample

1,334

Patients

Duration

24.6 mo

Median

Setting

Multicenter, international

Population Adult patients (18 years or older) with previously untreated stage III or IV classical Hodgkin's lymphoma.

Intervention A+AVD (brentuximab vedotin 1.2 mg/kg, doxorubicin 25 mg/m^2, vinblastine 6 mg/m^2, and dacarbazine 375 mg/m^2) administered on days 1 and 15 of each 28-day cycle for up to 6 cycles.

Comparator ABVD (doxorubicin 25 mg/m^2, bleomycin 10 U/m^2, vinblastine 6 mg/m^2, and dacarbazine 375 mg/m^2) administered on days 1 and 15 of each 28-day cycle for up to 6 cycles.

Outcome Modified progression-free survival (defined as the time to progression, death, or noncomplete response and use of subsequent anticancer therapy) assessed by an independent review committee.

Study Limitations

• The open-label design could introduce bias in toxicity reporting and investigator decisions, although the primary endpoint was centrally adjudicated.

• The use of 'modified' progression-free survival as a primary endpoint was unconventional because it included a noncomplete response (Deauville score 3-5) requiring alternative therapy as a failure event.

• The A+AVD regimen caused higher rates of peripheral neuropathy and myelosuppression, mandating the routine use of G-CSF prophylaxis.

• At the time of this initial publication, overall survival data were immature and did not show a statistically significant difference.

• A+AVD entails a substantially higher financial cost compared to generic ABVD.

Clinical Significance

ECHELON-1 established A+AVD as an efficacious, targeted frontline option for advanced Hodgkin lymphoma that successfully eliminated the risk of severe bleomycin-induced pulmonary toxicity. While it introduced higher rates of neutropenia and peripheral neuropathy requiring proactive management, the significant reduction in primary treatment failures fundamentally shifted standard-of-care guidelines.

Historical Context

For over three decades, ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) was the undisputed frontline standard for advanced classical Hodgkin lymphoma, offering high cure rates but carrying a notorious risk of potentially fatal bleomycin-induced pulmonary toxicity. Brentuximab vedotin, a CD30-directed antibody-drug conjugate, had proven highly effective in relapsed and refractory settings. ECHELON-1 was a landmark effort to safely integrate brentuximab vedotin into the frontline setting by substituting it for bleomycin. It represented one of the first major successful innovations over ABVD in frontline therapy, paving the way for the broad use of antibody-drug conjugates in early-line Hodgkin lymphoma treatment.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

Brentuximab vedotin replaces bleomycin in the A+AVD regimen for advanced Hodgkin lymphoma. What is the mechanism of action of brentuximab vedotin, and what specific cellular target does it exploit on the classic Reed-Sternberg cell?

Key Response

Brentuximab vedotin is an antibody-drug conjugate targeting CD30, a hallmark surface marker on classic Reed-Sternberg cells. Once bound, it is internalized and releases monomethyl auristatin E (MMAE), a potent microtubule-disrupting agent that induces apoptosis.

Resident

A 35-year-old patient with Stage IV Hodgkin lymphoma is starting A+AVD based on the ECHELON-1 trial. What two major adverse effects must you monitor for closely, and what prophylactic medication should be considered standard when using this regimen?

Key Response

The A+AVD regimen is associated with higher rates of peripheral neuropathy (due to the MMAE component of brentuximab) and febrile neutropenia compared to ABVD. Primary prophylaxis with G-CSF is strongly recommended when administering A+AVD to mitigate the severe neutropenia risk.

Fellow

The ECHELON-1 trial utilized a novel primary endpoint called modified progression-free survival (mPFS). How does mPFS differ from traditional PFS, and how might this endpoint influence the interpretation of frontline therapy efficacy in Hodgkin lymphoma?

Key Response

Modified PFS includes traditional events (progression, death) but also counts a less-than-complete response at the end of frontline therapy followed by subsequent anticancer therapy as an event. This was designed to capture patients who fail upfront therapy and need immediate salvage, which is highly relevant in a disease where the goal of frontline therapy is definitive cure.

Attending

While A+AVD showed a statistically significant improvement in modified PFS over ABVD, it comes with increased neuropathy and cost. How should we balance this upfront regimen against the modern PET-adapted approach, where bleomycin is dropped after a negative interim PET?

Key Response

Attending physicians must weigh the absolute PFS benefit of A+AVD against the high curability of HL with PET-adapted ABVD, which spares most patients bleomycin toxicity while reserving expensive or toxic salvage therapies for those who actually relapse or have positive interim PET scans. Patient age, IPS score, and baseline neuropathy or lung disease play a key role in tailoring this choice.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

ECHELON-1 did not mandate interim PET-driven treatment modifications. How does the lack of a dynamic, biomarker-adapted control arm affect the trial's external validity and the estimation of the true treatment effect size?

Key Response

By using a static ABVD control arm, the trial compares the experimental therapy to an older standard of care rather than the modern PET-adapted approach. This design choice maximizes the observable difference between arms but limits the generalizability of the effect size when applied to health systems that have fully adopted interim PET-driven de-escalation protocols.

Journal Editor

As a peer reviewer assessing the ECHELON-1 manuscript, what concerns might you raise regarding the decision to include modified PFS as the primary endpoint, and how does the unblinded assessment of non-complete response potentially introduce bias?

Key Response

A strict reviewer would flag that mPFS includes the initiation of subsequent therapy for an incomplete response, a clinical decision that can be subjective. If investigators are aware of the treatment arm or if local radiologic assessment of end-of-treatment PET scans is not perfectly aligned with central review, it introduces a risk of performance bias, artificially inflating the event rate in the control arm.

Guideline Committee

How should the ECHELON-1 findings be integrated into current NCCN or ESMO guidelines for advanced Hodgkin lymphoma? Specifically, does the evidence warrant replacing ABVD as the universally preferred frontline regimen?

Key Response

The committee would likely grant A+AVD a Category 1 recommendation but avoid making it the sole preferred regimen over ABVD. Given the high overall survival in advanced HL, the guidelines position A+AVD as an alternative preferred option particularly for patients with a high International Prognostic Score (IPS) or baseline pulmonary contraindications to bleomycin, while noting the mandatory need for G-CSF prophylaxis and the significant increase in peripheral neuropathy.

Clinical Landscape

Noteworthy Related Trials

2015

AETHERA Trial

n = 329 · Lancet

Tested

Brentuximab vedotin consolidation therapy

Population

Patients with Hodgkin's lymphoma at high risk of relapse after autologous stem-cell transplantation

Comparator

Placebo

Endpoint

Progression-free survival

Key result: Consolidation with brentuximab vedotin significantly improved progression-free survival compared to placebo in high-risk post-transplant patients.

2016

RATHL Trial

n = 1,214 · NEJM

Tested

PET-guided omission of bleomycin (AVD)

Population

Patients with advanced-stage classical Hodgkin's lymphoma

Comparator

Standard ABVD chemotherapy

Endpoint

Progression-free survival

Key result: Omitting bleomycin after a negative interim PET scan reduced pulmonary toxicity without significantly compromising progression-free survival.

2017

HD18 Trial

n = 2,101 · Lancet

Tested

PET-guided reduction to 4 cycles of escalated BEACOPP

Population

Patients with advanced-stage Hodgkin's lymphoma aged 18-60

Comparator

6 or 8 cycles of escalated BEACOPP

Endpoint

Progression-free survival

Key result: Shortening treatment to 4 cycles of escalated BEACOPP in PET2-negative patients maintained high efficacy while substantially reducing severe infections and toxicity.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis